GS1 US appoints Greg Bylo as Vice President of Healthcare

Bylo to lead GS1 Healthcare US Industry Initiative

GS1 US has appointed Greg Bylo as Vice President, Healthcare.In this role, Bylo is responsible for leading GS1 Healthcare US, an industry-wide initiative combining pharmaceutical, medical device, provider, and patient care professionals aimed at driving the adoption of GS1 Standards for improved patient safety and supply chain performance in the healthcare industry.

The initiative is also focused on GS1 Standards implementation to support the US Food and Drug Administration (FDA) Drug Supply Chain Security Act and Unique Device Identification (UDI) Rule requirements.

'Greg will be working with industry stakeholders to understand their collective objectives and offer strategic guidance on the use of standards and technology to improve business and clinical processes,' said Siobhan O'Bara, Senior Vice President, Industry Engagement, GS1 US.

Prior to joining GS1 US, Bylo was Senior Director of Global Supply Chain Support Services at Integra Life Sciences. He also spent more than 15 years at Becton Dickinson leading sales and operations planning and supply chain planning teams.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Serialisation: No more time to waste

One barrier to implementing product serialisation has been the variation and uncertainty of what would be required in the various regions around the world. Susan Birks talked to key players about how ready the industry is to meet the deadlines
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Subscribe now